"Thiazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms.
Descriptor ID |
D013844
|
MeSH Number(s) |
D02.886.675 D03.383.129.708
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiazoles".
Below are MeSH descriptors whose meaning is more specific than "Thiazoles".
This graph shows the total number of publications written about "Thiazoles" by people in this website by year, and whether "Thiazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 2 | 2 |
2004 | 0 | 1 | 1 |
2005 | 0 | 2 | 2 |
2006 | 0 | 2 | 2 |
2007 | 1 | 1 | 2 |
2009 | 2 | 0 | 2 |
2010 | 1 | 1 | 2 |
2012 | 1 | 0 | 1 |
2013 | 1 | 1 | 2 |
2014 | 0 | 1 | 1 |
2015 | 1 | 0 | 1 |
2016 | 5 | 1 | 6 |
2017 | 4 | 0 | 4 |
2018 | 3 | 3 | 6 |
2019 | 1 | 1 | 2 |
2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thiazoles" by people in Profiles.
-
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. J Thromb Haemost. 2021 12; 19(12):3008-3017.
-
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med. 2021 12 02; 385(23):2150-2160.
-
Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. Thromb Res. 2020 01; 185:13-19.
-
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019 11; 17(11):1866-1874.
-
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.
-
Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial. Am Heart J. 2018 11; 205:63-69.
-
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018 Aug; 118(8):1439-1449.
-
Edoxaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 07 05; 379(1):95-96.
-
Glycogen synthase kinase-3ß inhibition enhances myelination in preterm newborns with intraventricular hemorrhage, but not recombinant Wnt3A. Neurobiol Dis. 2018 10; 118:22-39.
-
Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. Thromb Haemost. 2018 01; 118(1):174-181.